Abaloparatide — Membership Pricing

Other medications in Bone Health

• Calcitonin
• Calcium Carbonate
• Denosumab
• Etidronate
• Romosozumab
• Teriparatide
• Zoledronic Acid

About Abaloparatide

Abaloparatide is a prescription medication used to treat osteoporosis, a condition that weakens bones and increases fracture risk. At TheDrugClub, we understand the importance of accessing vital medications like abaloparatide. We strive to help our members find significant savings, making essential treatments more manageable for your budget.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Abaloparatide is approved for (FDA label)

TYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.1 ) Treatment to increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.2 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.

Source: Read the full FDA label on DailyMed. Label effective date: August 11, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Abaloparatide (FDA label)

Injection: 3120 mcg/1.56 mL (2000 mcg/mL) of abaloparatide in clear, colorless solution in a single-patient-use prefilled pen. The prefilled pen delivers 30 doses of TYMLOS, each containing 80 mcg of abaloparatide in 40 mcL. Injection: 3120 mcg/1.56 ml (2000 mcg/ml) of abaloparatide in clear, colorless solution in a single-patient-use prefilled pen. The prefilled pen delivers 30 daily doses of 80 mcg abaloparatide in 40 mcl. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 712143d9-e21e-4013-bb3b-3426a21060a8. SPL document ID: f1834fb1-55c0-46ca-9da4-d03e867b3b8b. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Abaloparatide (FDA label)

The following adverse reactions are described in greater detail in other sections: Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] Risk of Osteosarcoma [see Warnings and Precautions (5.2) ] Orthostatic Hypotension [see Warnings and Precautions ( 5.3 )] Hypercalcemia [see Warnings and Precautions ( 5.4 )] Hypercalciuria and Urolithiasis [see Warnings and Precautions ( 5.5 )] Osteoporosis in postmenopausal women: The most common adverse reactions (incidence ≥2%) are hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, and vertigo. ( 6.1 ) Osteoporosis in men: The most common adverse reactions (incidence ≥2%) are injection site erythema, dizziness, arthralgia, injection site swelling, injection site pain, contusion, nausea, diarrhea, abdominal distension, abdominal pain, and bone pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Radius Health, Inc. at 1-855-672-3487 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 712143d9-e21e-4013-bb3b-3426a21060a8. SPL document ID: f1834fb1-55c0-46ca-9da4-d03e867b3b8b. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Abaloparatide (FDA label)

TYMLOS is contraindicated in patients with a history of severe hypersensitivity to abaloparatide or any of the inactive ingredients of TYMLOS. Reactions have included anaphylaxis, angioedema, dyspnea, and urticaria [see Warnings and Precautions (5.1) , Adverse Reactions ( 6.2 )] . Severe hypersensitivity to abaloparatide or any of the inactive ingredients of TYMLOS. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 712143d9-e21e-4013-bb3b-3426a21060a8. SPL document ID: f1834fb1-55c0-46ca-9da4-d03e867b3b8b. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Abaloparatide (FDA label)

Hypersensitivity Reactions: Anaphylaxis, angioedema, and urticaria have been reported in patients treated with parathyroid hormone analogs, including TYMLOS. If signs or symptoms of a hypersensitivity reaction occur, discontinue treatment with TYMLOS, initiate supportive care, and monitor until signs or symptoms resolve.

Source: FDA prescribing information (DailyMed). Set ID: 712143d9-e21e-4013-bb3b-3426a21060a8. SPL document ID: f1834fb1-55c0-46ca-9da4-d03e867b3b8b. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Abaloparatide (FDA label)

No specific drug-drug interaction studies have been performed [see Clinical Pharmacology ( 12.3 )] .

Source: FDA prescribing information (DailyMed). Set ID: 712143d9-e21e-4013-bb3b-3426a21060a8. SPL document ID: f1834fb1-55c0-46ca-9da4-d03e867b3b8b. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.